The estimated Net Worth of Biotech Fund I, L.P.Israel ... is at least 554 千$ dollars as of 7 February 2024. Biotech Israel owns over 27,847,159 units of Ayala Pharmaceuticals stock worth over 554,356$ and over the last few years Biotech sold ADXS stock worth over 0$.
Biotech has made over 2 trades of the Ayala Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently Biotech exercised 27,847,159 units of ADXS stock worth 11,138,864$ on 7 February 2024.
The largest trade Biotech's ever made was exercising 27,847,159 units of Ayala Pharmaceuticals stock on 7 February 2024 worth over 11,138,864$. On average, Biotech trades about 7,291,219 units every 28 days since 2023. As of 7 February 2024 Biotech still owns at least 27,717,808 units of Ayala Pharmaceuticals stock.
You can see the complete history of Biotech Israel stock trades at the bottom of the page.
Over the last 20 years, insiders at Ayala Pharmaceuticals have traded over 12,060,930$ worth of Ayala Pharmaceuticals stock and bought 7,108,817 units worth 19,940,745$ . The most active insiders traders include Biotech Fund I, L.P.Israel ...、Capital Partners Gp, L.L.C....、Thomas A Moore. On average, Ayala Pharmaceuticals executives and independent directors trade stock every 107 days with the average trade being worth of 12,473$. The most recent stock trade was executed by Biotech Fund I, L.P.Israel ... on 7 February 2024, trading 27,847,159 units of ADXS stock currently worth 11,138,864$.
advaxis (nasdaq: adxs) is a late -stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. the advaxis technology, using bioengineered live attenuated bacteria, listeria monocytogenes (lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
Ayala Pharmaceuticals executives and other stock owners filed with the SEC include: